Efficacy and Safety of Avatrombopag Combined With IST for the Treatment of HAAA and SAA With Abnormal Liver Function
Status:
Recruiting
Trial end date:
2024-06-28
Target enrollment:
Participant gender:
Summary
This is a multicenter, single-arm clinical study. The objective was to evaluate the efficacy
and safety of Avatrombopag combined with IST in very/sever aplastic anemia patients with
abnormal liver function or HAAA patients treated for the first time. The design was: Patients
received p-ATG for 5 consecutive days (day 1-5), at a dose of 20 mg/kg/day. Cyclosporine 3
mg/kg orally in two divided doses, with cyclosporine trough concentrations maintained at
200-250 ng/ml for 3 months to achieve maximum efficacy, and Avatrombopag, which was
administered in the dose of 40 mg orally once daily for a total of 12 weeks. Thirty-nine
patients are expected to be enrolled in this study. Evaluation endpoint: complete response
rate at 12 weeks of treatment.